Skip to content

Study · Animal study (in vivo) · rat · 2016

3 results

D-SAL and NAP: Two Peptides Sharing a SIP Domain.

Gozes I, Sragovich S, Schirer Y, Idan-Feldman A

Journal of molecular neuroscience : MN1 Jun 2016Cited by 15 (Europe PMC)

PMID26816081 (opens in a new tab)DOI10.1007/s12031-015-0701-8 (opens in a new tab)PepBankPUB-26816081
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, NAP prevented immediate sensory neuropathy.

    In plain wordsIn diabetic rats, NAP prevented immediate sensory neuropathy.

    Peptide
    Davunetide
    Outcome
    DecreaseImmediate sensory neuropathy
    Study

    ratn: not reported in source

    diabetes model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Results indicated an immediate sensory neuropathy in the diabetic model, which was prevented by both peptides and a later neuropathic phase, prevented only by NAP treatment.
    2 context sentences
    Summary · context
    Here, we aimed to further evaluate and correlate effects at the behavioral level, in a rat model of diabetes.
    Summary · context
    Peripheral neuropathy was tested by measuring the response to a thermal stimulus, and cognitive ability was measured by a social memory test and a spatial memory test using long- and short-term dependent tasks and a reference memory task.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, NAP prevented the later neuropathic phase.

    In plain wordsIn diabetic rats, NAP prevented the later neuropathic phase.

    Peptide
    Davunetide
    Outcome
    DecreaseLater neuropathic phase
    Study

    ratn: not reported in source

    diabetes model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Results indicated an immediate sensory neuropathy in the diabetic model, which was prevented by both peptides and a later neuropathic phase, prevented only by NAP treatment.
    2 context sentences
    Summary · context
    Here, we aimed to further evaluate and correlate effects at the behavioral level, in a rat model of diabetes.
    Summary · context
    Peripheral neuropathy was tested by measuring the response to a thermal stimulus, and cognitive ability was measured by a social memory test and a spatial memory test using long- and short-term dependent tasks and a reference memory task.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, NAP improved aspects of cognitive behavior and was more potent than D-SAL.

    In plain wordsIn diabetic rats, NAP improved aspects of cognitive behavior more potently than D-SAL.

    Peptide
    Davunetide
    Outcome
    IncreaseCognitive behavior
    Study

    ratn: not reported in source

    diabetes model
    Comparator
    D-SAL
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Each of the peptides improved different aspects of cognitive behavior, with NAP being more potent than D-SAL.
    2 context sentences
    Summary · context
    Here, we aimed to further evaluate and correlate effects at the behavioral level, in a rat model of diabetes.
    Summary · context
    Peripheral neuropathy was tested by measuring the response to a thermal stimulus, and cognitive ability was measured by a social memory test and a spatial memory test using long- and short-term dependent tasks and a reference memory task.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.